| Gorovitz & Borten, P.C. Attorneys at Law 400 Totten Pond Road, 2nd Floor Waltham, Massachusetts 02451 Tel: (781) 890-9095 |
| Thrombolytic Therapy for Stroke |
The rationale supporting the use of thrombolytic therapy is based on the
knowledge that most ischemic strokes are the result of thrombotic or
thromboembolic occlusion of the brain arteries. Thrombolytic therapy is of
proven benefit for selected patients with ischemic stroke. Thrombolytic agents
convert plasminogen to plasmin which breaks fibrin strands in intravascular
thrombi resulting in clot lysis and restoration of blood flow to the affected areas
of the brain. Interest in thrombolytic therapy for acute ischemic stroke was
triggered by the success of thrombolytic therapy in the management of acute
myocardial infarcts.
The administration of recombinant tissue plasminogen activator (tPA) has
revolutionized the acute management of stroke. Currently, tissue plasminogen
activator (tPA) is the only approved therapy for acute ischemic stroke. It
requires that a stroke be promptly diagnosed and treated as a time-critical
emergency. The report from the National Institute of Neurological Disorders and
Stroke (NINDS report) demonstrated substantial benefit from the intravenous
administration of tissue plasminogen activator (tPA) to a selected group of
patients with acute ischemic strokes of less than 3 hours duration from its onset.
Intra-arterial thrombolytic therapy can be administered either by regional or
local infusion directly into the thrombus using specialized catheters.
Advantages of this method include the improved diagnostic accuracy,
increased safety due to the administration of smaller amounts of drugs and the
increased rate of recanalization.
Patients who are not eligible for tissue plasminogen activator (tPA) therapy
should be evaluated for antithrombotic therapy. Heparin, low-molecular-weight
heparins and heparinoids as well as aspirin have been used for this purpose.
Use of antithrombotic therapy is aimed at reducing the risk of stroke
progression or recurrent cerebral thromboembolism and for the prevention of
venous thromboembolic complications such as deep vein thrombosis (DVT) or
pulmonary embolism (PE).
If you are suffering from complications due to a delayed diagnosis of a stroke or
the mismanagement of a stroke, let Dr. Borten and the Boston area medical
malpractice attorneys at Gorovitz & Borten review the specifics of your case.
review the specifics of your case. At Gorovitz & Borten we have the necessary
experience, understanding and resources available to properly evaluate the
complications of a stroke, and give you a timely assessment of its merits.
knowledge that most ischemic strokes are the result of thrombotic or
thromboembolic occlusion of the brain arteries. Thrombolytic therapy is of
proven benefit for selected patients with ischemic stroke. Thrombolytic agents
convert plasminogen to plasmin which breaks fibrin strands in intravascular
thrombi resulting in clot lysis and restoration of blood flow to the affected areas
of the brain. Interest in thrombolytic therapy for acute ischemic stroke was
triggered by the success of thrombolytic therapy in the management of acute
myocardial infarcts.
The administration of recombinant tissue plasminogen activator (tPA) has
revolutionized the acute management of stroke. Currently, tissue plasminogen
activator (tPA) is the only approved therapy for acute ischemic stroke. It
requires that a stroke be promptly diagnosed and treated as a time-critical
emergency. The report from the National Institute of Neurological Disorders and
Stroke (NINDS report) demonstrated substantial benefit from the intravenous
administration of tissue plasminogen activator (tPA) to a selected group of
patients with acute ischemic strokes of less than 3 hours duration from its onset.
Intra-arterial thrombolytic therapy can be administered either by regional or
local infusion directly into the thrombus using specialized catheters.
Advantages of this method include the improved diagnostic accuracy,
increased safety due to the administration of smaller amounts of drugs and the
increased rate of recanalization.
Patients who are not eligible for tissue plasminogen activator (tPA) therapy
should be evaluated for antithrombotic therapy. Heparin, low-molecular-weight
heparins and heparinoids as well as aspirin have been used for this purpose.
Use of antithrombotic therapy is aimed at reducing the risk of stroke
progression or recurrent cerebral thromboembolism and for the prevention of
venous thromboembolic complications such as deep vein thrombosis (DVT) or
pulmonary embolism (PE).
If you are suffering from complications due to a delayed diagnosis of a stroke or
the mismanagement of a stroke, let Dr. Borten and the Boston area medical
malpractice attorneys at Gorovitz & Borten review the specifics of your case.
review the specifics of your case. At Gorovitz & Borten we have the necessary
experience, understanding and resources available to properly evaluate the
complications of a stroke, and give you a timely assessment of its merits.
Contact Information
For a free confidential consultation and receive a response within 24 hours
(when possible), please contact us by phone, fax or e-mail with your question
or concern.
Telephone: 781-890-9095 - Fax: 781-890-9098
Directions
Electronic mail:
Questions or Inquiries to: inquiry@gbmedlaw.com
For a free confidential consultation and receive a response within 24 hours
(when possible), please contact us by phone, fax or e-mail with your question
or concern.
Telephone: 781-890-9095 - Fax: 781-890-9098
Directions
Electronic mail:
Questions or Inquiries to: inquiry@gbmedlaw.com
Website disclaimer: The materials on this website have been prepared by Gorovitz &
Borten, P.C. for informational purposes only and are not intended, and should not be
construed as legal advice. This information is not intended to create and receipt of it does
not constitute a lawyer-client relationship. Similarly, any submission or receipt of
information using electronic "Contact Us" form does not create a lawyer-client relationship.
Internet and online readers should not act upon any of the information contained on this
website without seeking professional counsel. (See Terms and Conditions).
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
 |